MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'biopharmaceuticals'. Sat, 03 Sep 2011 02:51:10 +0100 http://www.medworm.com/index.php?rid=4119715&cid=t_156392_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FxBlHrEJ5eEg%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that GCI Health hired Mark Davis to lead its Digital Health effort. Before joining the agency, he was director of social media at Novartis Pharmaceuticals, where he worked on developing regulatory and legal operating procedur... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4119715 Fri, 29 Oct 2010 12:00:48 +0100 4119715 http://www.medworm.com/index.php?rid=3999294&cid=t_156392_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FvYNUU0WT-Hs%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that AVEO Pharmaceuticals hired Michael Bailey as chief commercial officer. Before joining the drugmaker, he worked at Synta Pharmaceutials as senior vp of business development and chief commercial officer, and previously led... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3999294 Fri, 24 Sep 2010 12:24:55 +0100 3999294 http://www.medworm.com/index.php?rid=3784500&cid=t_156392_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FlKiFN8hyxGU%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Spectrum Pharmaceuticals hired George Tidmarsh as senior vice president, chief scientific officer and head of R&D operations. Tidmarsh founded Horizon Pharma and Threshold Pharmaceuticals, and also held various posi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3784500 Fri, 23 Jul 2010 13:06:49 +0100 3784500 http://www.medworm.com/index.php?rid=2977571&cid=t_156392_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FxYomIRth_jw%2F Top of the morning, everyone. And a pleasant one, it is. Of course, rousting one of the short people from bed is proving challenging today - those of you with adolescents may understand. Still, we soldier on. And that calls for a cup of stimulation or two. While we brace ourselves, here are a few items to help you ease in to your own routine. Have a great day… Bristol Buys Rights to RA Drug (Associated Press) Pfizer In Partnership With BMP In China (Reuters) Glaxo To Donate 50M H1N1 Vaccine Doses To WHO (Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=2977571 Tue, 10 Nov 2009 13:01:11 +0100 2977571 http://www.medworm.com/index.php?rid=1714174&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2541 At the American Chemical Society national conference last weekend, Rensselaer Polytechnic researcher Dr. Robert Linhart announced that his team may have built the first fully synthetic heparin. Whether or not you believe that the possibility of another contamination crisis of natural raw heparin exists, the potential for a heparin supply independent of the whims and [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1714174 Mon, 18 Aug 2008 16:56:49 +0100 1714174 http://www.medworm.com/index.php?rid=1709299&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F08%2Fgeneric-insulin-in-2008-dont-bet-on-it.html Remember Insmed? Well, back in February, I posted a story I called "Meet Mike Coleman", which was coined from the Pharmalot news story featuring a YouTube video entitled "Meet Mike, Your Generic Biologics Lobbyist". Well, this morning's Washington Post has another story on the company's marketing efforts to advocate legislation passes to permit biogenerics, which quite frankly, seems unlikely to pass in 2008, but I'd never say never when politics are concerned.One has to wonder, since the law currently considers insulin a "drug" not a biotech medicine, and under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, a "generic" doesn't have to be an exact duplicate of the brand-name original in order to be approved by the FDA. So why isn't Insmed applying to make generic insulin an... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1709299 Thu, 14 Aug 2008 14:00:00 +0100 1709299 http://www.medworm.com/index.php?rid=1696434&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2531 A large push by Las Vegas economic development authorities to lure biotech companies away from New Jersey, California, and other hotbeds has by and large come up empty. The promise of tax incentives and cheap land for development means little, it seems, if the biotech talent pool is dry. The LV Review-Journal reports. –PWT (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1696434 Mon, 11 Aug 2008 13:24:02 +0100 1696434 http://www.medworm.com/index.php?rid=1652567&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2361 Fierce Vaccines  just spotlighted an article from this week’s Scientific American, on a clinical trial of a vacccine for non Hodgkins lymphoma, which was derived by tobacco plants. Researchers produced tumor-fighting antigen within the plants by first extracting the gene coding for the antigen from white blood cells in patients’ tumors, then inserting it into a tobacco [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1652567 Thu, 24 Jul 2008 14:24:22 +0100 1652567 http://www.medworm.com/index.php?rid=1635188&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2331 Just discovered the “PCR Song,” which predates the Agilent video…with a “we are the world” theme.   High school biotech students are also flooding YouTube with Biotech rap  new dance forms…and this rather creative DNA Replication Song.   Lots of fun (but hope they didn’t submit these as their senior projects….) (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1635188 Thu, 17 Jul 2008 21:22:56 +0100 1635188 http://www.medworm.com/index.php?rid=1543934&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2231 This article from Wired News asked whether Mr. Schwarzenegger is advancing biotechnology quite as much as he claimed to be in his BIO speech last week.  At issue:  cease-and-desist letters sent to genetic testing companies. (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1543934 Wed, 25 Jun 2008 19:15:31 +0100 1543934 http://www.medworm.com/index.php?rid=1531697&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2171 Spoke briefly with one, Michael Kowolenko, SVP of biopharmaceutical manufacturing at Wyeth, who talked about the industry’s fear of change, why it exists and offered some suggestions on what to do about it. Below are some (raw) audio snippets of the interview. An Interview with Michael Kowolenko of Wyeth Biopharma, Part One An Interview with Michael Kowolenko [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1531697 Fri, 20 Jun 2008 17:10:59 +0100 1531697 http://www.medworm.com/index.php?rid=1526783&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D2021 That’s how Control magazine’s executive editor Jim Montague described the pharmaceutical industry in a recent and very memorable op-ed (read it here), in which he interviews experts including E-55 insider Gawayne Mahboubian-Jones. Jim brings to the the “so what” detachment of one who has covered PAT and process control as it has advanced in other industries over [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1526783 Tue, 17 Jun 2008 03:20:32 +0100 1526783 http://www.medworm.com/index.php?rid=1362495&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1721 Geez Louise, could the pharma employment picture get much bleaker? On Friday, Schering-Plough announced it would cut 10% of its 55,000 global employees within the next two years, and that the company’s Kenilworth, N.J. headquarters would feel the most pain. Let’s empathize for a moment: slowly say, “fifty-five hundred people out on the street.” Ouch. Double [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1362495 Thu, 10 Apr 2008 00:49:29 +0100 1362495 http://www.medworm.com/index.php?rid=1307753&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F03%2Frep-eshoo-decries-congressional.html What would you say to a Congresswoman who behaves like a hypocrite? Well, California's 14th District (an area I'm very familiar with, having lived in the district for nearly a decade during the 1990's) House Representative Anna Eshoo deserves just such a rebuke today. Ms. Eshoo, who was on the San Mateo County Board of Supervisors when I resided in Foster City, represents the district where many biotechnology firms and venture capitalists are based, encompassing much of Silicon Valley and stretches up the San Francisco Peninsula.Just what has she done? Well, she has sponsored legislation aimed at "cleaning up the House" which she claims is to restore the confidence of the American people in their government. Sounds convincing so far. One of the key elements in her proposed legislation aims... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1307753 Mon, 17 Mar 2008 15:45:00 +0100 1307753 http://www.medworm.com/index.php?rid=1280795&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F03%2Ffda-needs-your-input-on-diabetes.html On Tuesday, I wrote about the opportunity for people with diabetes to attend the NIH/NIDDK's jointly-sponsored (along with JDRF) "Artificial Pancreas Workshop" in July. But I also mentioned that it was merely the first opportunity for you as patients to contribute something by representing real-life patient needs to our Government-funded agencies.Another opportunity you should be aware of is that the FDA has just issued a document with Draft Guidance for Industry for Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention, which provides recommendations to industry regarding the development of drugs and more specifically, therapeutic biologics regulated within the Center for Drug Evaluation and Research (CDER) in the Food and Drug Administration (FDA) for... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1280795 Wed, 05 Mar 2008 17:00:00 +0100 1280795 http://www.medworm.com/index.php?rid=1222378&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F02%2Fmeet-mike-coleman.html This morning, the blog Pharmalot had a posting entitled "Meet Mike, Your Generic Biologics Lobbyist", and I thought it would be appropriate to reiterate the need for Congress to move forward on this very issue. It was indeed a surprise to many (including me), but as I posted last week, even President Bush's 2008 budget calls for Congress to pass legislation to enable generic biopharmaceuticals.Last week, Insmed had one of its scientists, Mike Coleman, offer a "researcher's view" of the value of generic biopharmaceuticals. Coleman makes for an unusual lobbyist. But apparently Insmed, which has projects under way to develop several different generic biopharmaceuticals, is banking on a new 'educational campaign,' another way of saying public relations (PR), to influence Washington and the pub... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1222378 Mon, 11 Feb 2008 17:00:00 +0100 1222378 http://www.medworm.com/index.php?rid=1215341&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2008%2F02%2Fgood-news-in-last-bush-budget.html You might be surprised to hear me write that. To be sure, I cannot stand the Food and Drug Administration's user-fee system, and some have complained that the Bush budgets have consistently short-changes the FDA. But all things considered, I suspect we won't see any progress on either issue during 2008. But I did find what I believe to be good news in the Bush budget.As my readers know, I chronicled the story about impediments to new competition in the insulin market (see here for the original article, and provided that Google's Blogger cooperates, some fairly extensive follow-up coverage might also be accessible). Unfortunately, last year -- thanks largely to lobbyists for the pharmaceutical industry -- the U.S. Congress delayed passing legislation which would have removed the final imped... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1215341 Thu, 07 Feb 2008 14:00:00 +0100 1215341 http://www.medworm.com/index.php?rid=1158450&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1432 This is pretty old news, but it certainly took me by surprise. Just glanced at the online masthead and the byline of an article from the November 2007 issue of Biopharm International and learned that Dr. Hussain has moved from Sandoz to… Philip Morris International?  (OK.  Talk amongst yourselves….) His new title is :  Vice President of [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1158450 Thu, 17 Jan 2008 14:37:44 +0100 1158450 http://www.medworm.com/index.php?rid=1024336&cid=t_156392_134_f&fid=35152&url=http%3A%2F%2Fsstrumello.blogspot.com%2F2007%2F11%2Fbig-pharma-lobbyists-delay-generic.html As the D-Blogger community already discovered from Vivian's post, our do-nothing Congress has delayed passing legislation (until 2008) which would remove the final impediments for generic insulin, not to mention other (in the words of the FDA) "follow-on" protein products (that bill is known as S. 623/H.R. 1038, the "Access to Life-Saving Medicine Act of 2007").As I have chronicled throughout the year, the reasons for lack of generic insulin are multi-faceted, but the biggest single reason is that manufacturers of generic products, which include such well-regarded manufacturers such as Novartis' Sandoz unit, Israel-based Teva Pharmaceuticals, and U.S.-based Barr Pharmaceuticals among others are lacking guidance from the U.S. Food and Drug Administration on how to apply for and obtain appro... Scott's Web Log blogs http://www.medworm.com/rss/comments.php?id=1024336 Tue, 13 Nov 2007 15:50:00 +0100 1024336 http://www.medworm.com/index.php?rid=1018961&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1381 FDA issued a press release today (see below), noting that the Agency is calling for safety-related labeling changes for three biopharmaceuticals used to treat certain types of anemia. The release suggests that erythropoiesis-stimulating agents (ESAs) may pose serious health risks and have questionable efficacy in alleviating symptoms of anemia and fatigue in cancer patients. In addition to [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1018961 Sat, 10 Nov 2007 15:38:27 +0100 1018961 http://www.medworm.com/index.php?rid=1017860&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1381 FDA issued a press release today (see below), noting that the Agency is calling for safety-related labeling changes for three biopharmaceuticals used to treat certain types of anemia. The release suggests that erythropoiesis-stimulating agents (ESAs) may pose serious health risks and have questionable efficacy in alleviating symptoms of anemia and fatigue in cancer patients. In addition to [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=1017860 Fri, 09 Nov 2007 21:53:12 +0100 1017860 http://www.medworm.com/index.php?rid=987254&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1359 Ireland has had some setbacks recently, since Amgen postponed construction of a major biopharma plant in Cork.  Puerto Rico has seen some plant closures.  But for Singapore, so far, the news is all “expansion.” Novartis has recently built a tableting plant in Singapore and today disclosed that it will build a $700-million biopharmaceutical plant there.  For [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=987254 Mon, 29 Oct 2007 14:59:08 +0100 987254 http://www.medworm.com/index.php?rid=947470&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1327 http://www.reuters.com/article/marketsNews/idUSWEN165220071012 (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=947470 Fri, 12 Oct 2007 22:07:31 +0100 947470 http://www.medworm.com/index.php?rid=918144&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1324 I ran into an interesting article just as my EuroBio ‘party’ came to an end… John Forbes of Fortune recently reported that while biotech has led a charmed existence in the U.S. due to the complexity of its products, Congress and FDA are under pressure to create inexpensive biosimilars. The European Commission seems to have already created [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=918144 Mon, 01 Oct 2007 21:43:02 +0100 918144 http://www.medworm.com/index.php?rid=912198&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1323 One thing I was definitely surprised by was how many Americans were perusing the booths lectures at EuroBio…especially when I stumbled into the BioPartnering booths which were reserved for collaboration opportunities between industry and academia as well as tech transfer. Over 600 companies were represented as well as 100 academic institutions/organizations participated in the BioPartnering [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=912198 Fri, 28 Sep 2007 17:21:33 +0100 912198 http://www.medworm.com/index.php?rid=908791&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1322 Well I have successfully landed in Lille, France after an always-encouraging 3-hour flight delay at O’Hare. Fortunately enough this delay was quickly made up by Europe’s high speed TGV, and I was off to explore the small city of Lille which is located one hour north of Paris and half an hour south of Belgium [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=908791 Thu, 27 Sep 2007 18:09:43 +0100 908791 http://www.medworm.com/index.php?rid=904631&cid=t_156392_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F161496556%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Here are some of the latest moves… Lilly names Lauren Marangell as a Distinguished Scholar; Cardinal Health named ceo R. Kerry Clark as chairman; Shire appointed Sylvie Gregoire as prez, human genetic therapies biz; Cell Therapeutics adds Richard Love to its board; MacroGenics named Jeff Buchalter as chairman; Stiefel Labs appointed Lodewijk de Vink, to its board; Keryx Biopharmaceuticals named Mike Tarnok to its board; Gen-Probe named John Martin to its board; CG Therapeutics appointed Chris Henney ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=904631 Wed, 26 Sep 2007 11:29:25 +0100 904631 http://www.medworm.com/index.php?rid=763190&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1294 Reuters reported this week that a patient who became ill following two experimental gene therapy injections for arthritis has died. U.S. health regulators are investigating the cause, officials said yesterday. The gene therapy trial by Targeted Genetics Corp. was placed on hold before the death, after the patient suffered a serious, unidentified health problem. The hold [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=763190 Fri, 27 Jul 2007 19:18:32 +0100 763190 http://www.medworm.com/index.php?rid=751835&cid=t_156392_150_f&fid=35779&url=http%3A%2F%2Fwww.pharmamanufacturing.com%2Fonpharma%2F%3Fp%3D1284 Well, I may not be able to get any of you to comment on THIS blog, but “BIOPh.D” had the following insightful comments to share on our June cover story on Offshoring/Outsourcing on Biotech Blog. For more comments on the article, in an interesting online discussion thread, please visit Science Magazine’s outstanding Careers Forum, moderated by [...] (Source: On Pharma) On Pharma blogs http://www.medworm.com/rss/comments.php?id=751835 Mon, 23 Jul 2007 22:42:04 +0100 751835